Latest
Does glucosamine accelerate Alzheimer’s? A big claim, a small denominator
The First Oral Carbapenem Arrives - Tebipenem pivoxil (Utebzi): what it is, where it earns its place, and where it absolutely does not
Baxdrostat vs. Spironolactone: A New Mechanism Meets an Old Bargain - THE $5-BILLION QUESTION
IV Iron in Oncology: Time to Rethink Your Default
When the New β-Lactam/β-Lactamase Inhibitors Aren’t Enough
Asundexian for Secondary Stroke Prevention OCEANIC-STROKE — A Three-Lens Critical Appraisal
OCEANIC-STROKE met its primary endpoint with a 26% relative reduction in ischemic stroke and no excess major bleeding — but the prespecified hierarchy broke at the 90-day endpoint. A statistician, a neurologist, and a researcher walk into a journal club. Here's what they each see.
Beyond Weight Loss: Reading the GLP-1 Side Effect Profile in Real Numbers A field guide for clinicians who are tired of being shown hazard ratios without denominators.
The Aspiration Anaerobe Myth What actually colonizes the aerodigestive tract — and why reflexive Zosyn for “possible aspiration” fails basic microbiology
Flecainide After PCI: 35 Years After CAST, Is It Time to Reconsider Class Ic Antiarrhythmics in Coronary Artery Disease?
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Surviving Sepsis Campaign 2026: A Comprehensive Pharmacotherapy Review
The SSC 2026 Guidelines represent the most comprehensive sepsis update since 2021 — with major changes to antibiotic selection, vasopressor targets, fluid resuscitation, and a new strong recommendation for prolonged beta-lactam infusion.
pharmacology
Time of Death: Diphenhydramine — A Pharmacist's Case for Abandoning a Relic of 20th-Century Medicine
Diphenhydramine has occupied American medicine for over 70 years. A pharmacologist with 30 years of clinical experience makes the case that it's time to stop prescribing out of habit and start prescribing based on evidence.
Infectious Diseases
Rethinking C. diff Treatment: Is Fidaxomicin Worth the Money?
The TAPER-V trial forces us to ask a question we should have been asking all along — would fidaxomicin have demonstrated superiority if the original trials had used longer follow-up?
cardiology
2026 ACC/AHA Dyslipidemia Guideline: A Comprehensive Pharmacotherapy Review
The 2026 ACC/AHA Dyslipidemia Guideline represents the most significant overhaul of lipid management since 2018 — introducing specific cholesterol targets and an expanded pharmacotherapeutic armamentarium.